Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 14, 2022

SELL
$36.54 - $48.66 $107,829 - $143,595
-2,951 Reduced 20.76%
11,265 $498,000
Q2 2022

Aug 09, 2022

BUY
$31.71 - $43.0 $101,281 - $137,342
3,194 Added 28.98%
14,216 $526,000
Q1 2022

May 04, 2022

SELL
$29.88 - $37.04 $48,674 - $60,338
-1,629 Reduced 12.88%
11,022 $408,000
Q4 2021

Feb 09, 2022

BUY
$25.61 - $35.1 $1,229 - $1,684
48 Added 0.38%
12,651 $385,000
Q3 2021

Nov 04, 2021

SELL
$33.54 - $40.55 $18,983 - $22,951
-566 Reduced 4.3%
12,603 $423,000
Q2 2021

Aug 12, 2021

SELL
$34.54 - $47.25 $1.14 Million - $1.56 Million
-32,964 Reduced 71.45%
13,169 $525,000
Q1 2021

May 10, 2021

BUY
$42.51 - $63.78 $1.43 Million - $2.14 Million
33,597 Added 268.0%
46,133 $2.07 Million
Q4 2020

Feb 16, 2021

BUY
$45.3 - $60.27 $145,730 - $193,888
3,217 Added 34.52%
12,536 $709,000
Q2 2020

Aug 10, 2020

SELL
$46.85 - $61.05 $209,700 - $273,259
-4,476 Reduced 32.45%
9,319 $549,000
Q1 2020

May 11, 2020

SELL
$41.6 - $63.4 $5,283 - $8,051
-127 Reduced 0.91%
13,795 $652,000
Q4 2019

Feb 13, 2020

SELL
$53.85 - $65.27 $157,457 - $190,849
-2,924 Reduced 17.36%
13,922 $841,000
Q3 2019

Nov 12, 2019

SELL
$59.06 - $72.15 $4,370 - $5,339
-74 Reduced 0.44%
16,846 $1.01 Million
Q2 2019

Aug 12, 2019

BUY
$62.09 - $86.14 $174,348 - $241,881
2,808 Added 19.9%
16,920 $1.09 Million
Q4 2018

Feb 13, 2019

SELL
$43.37 - $59.54 $52,044 - $71,448
-1,200 Reduced 7.84%
14,112 $763,000
Q2 2018

Aug 10, 2018

SELL
$40.53 - $50.7 $33,194 - $41,523
-819 Reduced 5.08%
15,312 $638,000
Q1 2018

May 14, 2018

BUY
$44.08 - $55.05 $711,054 - $888,011
16,131 New
16,131 $711,000

Others Institutions Holding IONS

About IONIS PHARMACEUTICALS INC


  • Ticker IONS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 141,940,992
  • Market Cap $4.71B
  • Description
  • Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for famil...
More about IONS
Track This Portfolio

Track Shell Asset Management CO Portfolio

Follow Shell Asset Management CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Shell Asset Management CO, based on Form 13F filings with the SEC.

News

Stay updated on Shell Asset Management CO with notifications on news.